Search
Sepiapterin
go.drugbank.com/drugs/DB16326ApprovedInvestigational[L53548,L53593] Sepiapterin was granted marketing authorization by the European Commission in June 2025 and by the US FDA in July 2025 for the treatment of adults and children with phenylketonuria. … Sepiapterin is a small molecule activator of phenylalanine hydroxylase (PAH) used to reduce phenyalanine levels in patients with phenylketonuria.
Propylthiouracil
go.drugbank.com/drugs/DB00550ApprovedIt is used in the treatment of hyperthyroidism. (From Martindale, The Extra Pharmacopeoia, 30th ed, p534)
Penbutolol
go.drugbank.com/drugs/DB01359ApprovedInvestigationalWithdrawnThis binding characteristic of penbutolol is being investigated for its implications in Antidepressant Therapy. … Penbutolol is a drug in the beta-blocker class used to treat hypertension. Penbutolol binds both beta-1 and beta-2 adrenergic receptors, rendering it a non-selective beta-blocker.
Technetium Tc-99m medronate
go.drugbank.com/drugs/DB09138ApprovedInvestigationalLike other bisphosphonates used in the treatment of osteoporosis, medronic acid binds to the hydroxyapatite crystals within bone, and in this way localizes the drug to bone for delineation of areas of … Technetium (99mTc) medronic acid is a pharmaceutical product used in nuclear medicine imaging. It is composed of a technetium ion complexed with medronic acid, a type of bisphosphonate.
Synonyms: AN-MDPCategories: Compounds used in a research, industrial, or household settingRepotrectinib
go.drugbank.com/drugs/DB16826ApprovedInvestigationalThis approval is based on favorable results from the TRIDENT-1 study, where the objective response rate was 79% in TKI-naive patients and 38% in TKI-pretreated patients respectively.[L48741] … Repotrectinib is a next-generation tyrosine kinase inhibitor (TKI) specifically designed to address resistance in the treatment of non-small cell lung cancer (NSCLC), specifically due to mutations in the
mRNA-1010
go.drugbank.com/drugs/DB22484Approved[L64058] The FDA approved mFLUSIVA on August 5, 2026 for active immunization against influenza in adults 50 years of age and older, making it the first mRNA-based influenza vaccine approved in the United … benefit to be confirmed in a postmarketing trial.
Categories: Complex MixturesDonanemab
go.drugbank.com/drugs/DB16647ApprovedInvestigational[A232214] On July 2, 2024, donanemab was approved by the FDA for the treatment of AD in patients with mild cognitive impairment or dementia symptoms. … Donanemab is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against insoluble N-truncated pyroglutamate amyloid beta (Aβ), [L50978] which is found in the brain amyloid plaques that
Picrotoxin
go.drugbank.com/drugs/DB00466ExperimentalAlthough it is most often used as a research tool, it has been used as a CNS stimulant and an antidote in poisoning by CNS depressants, especially the barbiturates. [PubChem]
Categories: Compounds used in a research, industrial, or household setting, Complex MixturesBrexpiprazole
go.drugbank.com/drugs/DB09128ApprovedInvestigational[A182186, A38385, A259661] Brexpiprazole was first approved by the FDA on July 10, 2015. … Compared to aripiprazole, brexpiprazole has less potential for partial agonist-mediated adverse effects such as extrapyramidal symptoms, which is attributed to lower intrinsic activity at the D2 receptor